

MEDICINES FORMULARY
MARCH 2019

This version supersedes all previous versions for Medicines Formulary

Policy title	Medicines Formulary
Policy reference	PHA05
Policy category	Pharmacy
Relevant to	All staff handling medicines
Date published	March 2019
Implementation date	March 2019
Date last reviewed	January 2017
Next review date	Following DTC formulary decisions as and when applicable
Policy lead	Chief Pharmacist

Contact details Email: lucy.reeves@candi.nhs.uk Telephone:

Accountable director Dr Vincent Kirchner, Medical Director

Approved by (Group/Comm): Drug and Therapeutics Committee
March 2019

Ratified by (Committee):

Document history	Date	Version	Summary of amendments
	March 2019	14	Various amendments including addition of LMWHs, emergency bag medicines and phosphodiesterase type 5 inhibitors
	Jan 2017	13	New inclusion / amendment
	Dec 2016	12	New inclusion
	Dec 2015	11	New inclusion
	Sep 2015	10	Removal
	Apr 2015	9	Review of NMP approvals
	Feb 2015	8	New inclusions / removal
	Sep 2014	7	New inclusions

Membership of the policy development/ review team
Audrey Coker, Lead Pharmacist
Lead Pharmacists, Chief Pharmacist

Consultation

Drug and Therapeutics Committee members

DO NOT AMEND THIS DOCUMENT

Further copies of this document can be found on the Foundation Trust intranet.

Camden & Islington NHS Foundation Trust Medicines Formulary

Medicines Formulary Policy

The formulary is a list of medicines approved for use (BNF limits) within the Trust. The process for introducing medicines onto the Trust formulary is documented in the Trust Medicines Formulary Policy. The C&I FT formulary applies only to psychiatric medicines. All physical medicines should adhere to local acute trust and primary care policies and procedures. For medicines not included in this list refer to the Medicines Formulary Policy (Section 7: Use of non-formulary medicines). Refer to the Trust Medicines Management Policy (Appendix 5: Policy for the off-label use of medicines and unlicensed medicines) for further information on unlicensed medicines (ULM) and off-label uses and the approval process.

Independent Non Medical Prescribers: Scope of practice

Independent prescribing must be within the limits of the Trust Non Medical Prescribing Policy, which is for patients with an existing diagnosis who have been seen by the Consultant within the last year and must be within their scope of practice. Independent Non Medical Prescribers working in Addiction Services may only prescribe medicines listed within the 'Medicines used in substance dependence' section of the formulary (unless a specific exemption is stated). Independent Non Medical Prescribers may only prescribe medicines listed for nicotine dependence within the 'Medicines used in nicotine dependence' section.

Prescribing and Treatment Guidelines

This is not a guideline and does not make recommendations about treatment. Reference should be made to the Trust treatment guidelines on Trustnet or the current edition of Maudsley & Oxleas Prescribing Guidelines. Please consult the current BNF for prescribing information and/or the Summary of Product Characteristics (SPC) for the respective medicine, available at <http://www.medicines.org.uk/>

The formulary list below generally follows the BNF categorisation system. Approved unlicensed medicines and off-label use of medicines are annotated where appropriate.

BNF: 1. 2.2 Laxatives

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Osmotic laxatives	Lactulose	Solution	Approved: treatment of clozapine induced constipation	

BNF: 2.4.1 Beta-blockers in the management of autonomic symptoms of anxiety

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Beta-blockers	Propranolol	Tablet	Approved: Autonomic symptoms of anxiety	

BNF: 3.2 Management of disturbed behaviour

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Antihistamine	Promethazine	Injection Tablets, liquid	Approved (2nd line option): off-label use for treatment of acute phase of mania and aggression / rapid tranquilisation	Trust guidance: Rapid Tranquilisation guidelines

BNF: 4.1 Medicines for Dementia

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Acetylcholinesterase inhibitors	Donepezil	Tablets Tablet orodispersible	Approved (1st line option): mild to moderate dementia in Alzheimer's disease, off-label use in severe dementia where continued benefit to treatment; off-label use for BPSD in dementia with Lewy Body. Established diagnosis of Alzheimer's disease: Co-prescription with memantine may be considered for moderate disease and offered for severe disease.	SAMH initiation only NICE(NG97) ; (TA217)
	Galantamine	Tablet Capsule MR Solution	Approved (1st line option): mild to moderate dementia in Alzheimer's disease, off-label use in severe dementia where continued benefit to treatment; off-label use for BPSD in dementia with Lewy Body. Established diagnosis of Alzheimer's disease: Co-prescription with memantine may be considered for moderate disease and offered for severe disease.	SAMH initiation only NICE((NG97); (TA217)

	Rivastigmine	Capsule Patch	Approved (1st line option): mild to moderate dementia in Alzheimer's disease, off-label use in severe dementia where continued benefit to treatment; off-label use for BPSD in dementia with Lewy Body. Established diagnosis of Alzheimer's disease: Co-prescription with memantine may be considered for moderate disease and offered for severe disease.	SAMH initiation only NICE((NG97) ; (TA217)
Glutamate antagonist	Memantine	Tablets	Approved (2nd line option): moderate and severe dementia Alzheimer's disease where AChEI not tolerated or contraindicated. Co-prescription with a AChEI may be considered for moderate disease and offered for severe disease.	SAMH initiation only NICE (NG97) ; (TA217)

BNF: 4.2 Antiepileptics in the management of anxiety

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Antiepileptic	Pregabalin	Capsules	Approved (3rd line option): treatment of GAD, where either two SSRIs or one SSRI and an SNRI have been tried and failed or not tolerated	Higher cost preparation Prescribe as twice daily dosing regime. Caution: risk of misuse in SMS/prison services NICE(CG113)

BNF: 4.2 Anticonvulsants prescribed as antimanic medicines

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Anticonvulsant medicines	Lamotrigine	Tablet Dispersible tablet	Approved: Prophylaxis of depressive episode in BPAD. Treatment of depressive episodes of BPAD (off label indication).	NICE(CG185)
	Sodium valproate	Tablet crushable Tablet e/c Tablet MR Liquid	Approved: Off-label use in bipolar affective disorder (BPAD). Not approved for women of child-bearing age. Requires a pregnancy prevention programme, a risk acknowledgement form and a non-formulary form to be in place.	NICE(CG185)

(Lithium – see BNF 4.3.3).

BNF: 4.3.1 Anxiolytics

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Benzodiazepines	Chlordiazepoxide	Capsules	Approved: anxiety (short term use); alcohol withdrawal	
	Clonazepam	Tablet Liquid	Approved: off-label use anxiety (short term)	
	Diazepam	Tablet Oral solution	Approved (1st line option): anxiety (short term use); alcohol withdrawal	
	Lorazepam	Tablet Injection	Approved (1st line option): anxiety (short term use); off-label use for treatment of acute phase of mania and aggression / rapid tranquillisation	Trust guidance: Rapid Tranquilisation guidelines NICE (NG10)
Buspirone	Buspirone hydrochloride	Tablet	Approved: anxiety (short term use)	Anxiety Disorder Prescribing Guidelines

BNF: 4.3.1 Benzodiazepines

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Benzodiazepines	Diazepam Chlordiazepoxide Lorazepam Clonazepam		Approved: Off label use for treatment of acute phase of mania.	Should not be used for long periods because of risk of dependence. NICE(CG185)

BNF: 4.3.1 Medicines for GHB withdrawal symptoms

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Gamma-hydroxy butyrate (GHB) Dependence	Diazepam	All oral preparations	Approved: off-label use in treatment of GHB withdrawal symptoms	Management and detoxification of GHB and GBL guidelines

Baclofen – see BNF 10.3.4.

BNF: 4.3.1 Benzodiazepine dependence

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Benzodiazepine dependence	Diazepam	Tablet Liquid	Approved: off-label use in benzodiazepine dependence	Prescribing Guidance for Substance Misuse Services

BNF: 4.3.2 CNS stimulants and other medicines used for Attention Deficit Hyperactivity Disorder (ADHD)

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
CNS Stimulants	Methylphenidate hydrochloride CD	Tablet (immediate release) Concerta XL® tablets [22/78] Equasym XL® capsules [30/70] Medikinet XL® capsules [50/50]	Approved: Off-label use in adult (>18years) Attention deficit hyperactivity disorder (ADHD)	XL preparations should be prescribed by specific brand name NICE(NG87); [NICE(TA98)]
	Dexamphetamine CD	tablets	Approved: (3rd line option) Off-label use in adult (>18years) Attention deficit hyperactivity disorder (ADHD)	NICE(NG87); [NICE(TA98)]
	Lisdexamfetamine CD	Capsulea	Approved: (1st line option) Off-label use in adult (>18years) Attention deficit hyperactivity disorder (ADHD)	Joint first line with methylphenidate (nice.org.uk/guidance/ng87)
Non-CNS Stimulants	Atomoxetine	Capsules	Approved: Off-label use in adult (>18years) Attention deficit hyperactivity disorder (ADHD)	NICE(NG87); [NICE(TA98)]

BNF: 4.3.2 CNS stimulants for dexamphetamine dependence

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
CNS stimulants	Dexamphetamine CD	tablets	Treatment of drug addiction by consultants	SMS consultant approval and initiation

BNF: 4.3.3 Antimanic Medicines

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Lithium	Lithium carbonate	Tablet (Priadel®)	Approved: treatment and prophylaxis of mania, bipolar disorder and recurrent depression.	Must be prescribed by brand. Preparations vary widely in bioavailability: changing preparations requires the same precautions as initiation of treatment. Note: lithium carbonate 200mg = lithium citrate 509mg NICE(CG185)
	Lithium citrate	Liquid (Pride) 520mg/5ml (5ml = 204mg lithium carbonate) Liquid (Li-liquid) 509mg/5ml (5ml = 200mg lithium carbonate)		
	Semisodium valproate (Depakote®)	Tablet e/c	Not Approved in any patient group.	Higher cost preparation. MHRA requirement for women in child-bearing age apply.

BNF: 4.3.4 Antidepressant Medicines
Tricyclic and related antidepressant medicines

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Tricyclic antidepressants	Amitriptyline hydrochloride	Tablet Liquid	Approved: Depression	Amitriptyline particularly dangerous in overdose ¹ Prescribing guidelines for the management of depression NICE(CG90);(CG91);(CG185)
	Clomipramine hydrochloride	Capsules	Approved: Depression, phobic & obsessional states, off-label use panic disorder	Prescribing guidelines for the management of depression NICE(CG90);(CG91);(CG185); (CG113)
	Imipramine hydrochloride	Tablet	Approved: Depression; off label use panic disorder	Prescribing guidelines for the management of depression NICE(CG90);(CG91);(CG185); (CG113)
	Lofepramine	Tablet Liquid	Approved: Depression	Prescribing guidelines for the management of depression NICE(CG90);(CG91);(CG185)

Related antidepressants	Mianserin hydrochloride	Tablet	Approved: Depression	Prescribing guidelines for the management of depression See BNF advice regarding blood monitoring before prescribing NICE(CG90);(CG91);(CG185)
	Trazadone	Tablets, Liquid	Approved: Depression	Prescribing guidelines for the management of depression

BNF: 4.3.4 Monoamine-Oxidase Inhibitors (MAOIs)

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
MAOIs	Phenelzine	Tablet	Approved: Depression, social anxiety disorder (off –label)	Prescribing guidelines for the management of depression Less suitable for prescribing due to dangers of dietary & medicine interactions NICE(CG90);(CG91);(CG185) (CG 159)
Reversible MAOIs	Moclobemide	Tablet	Approved: Depression, social anxiety disorder	Prescribing guidelines for the management of depression NICE(CG90);(CG91);(CG185) (CG159)

BNF: 4.3.4 Selective Serotonin Re-uptake Inhibitors (SSRIs)

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
SSRIs	Citalopram	Tablet Liquid (Cipramil® oral drops)	Approved (1st line option*): Depression; panic disorder; off-label use in generalised anxiety disorder (GAD)	Prescribing guidelines for the management of depression *Associated with dose related QT prolongation, therefore avoid in specific patient groups – see BNF. 4 drops (8mg) Cipramil® oral drops is equivalent in therapeutic effect to 10mg citalopram tablet. NICE(CG90/91);(CG91);(CG185); (CG113)

	Fluoxetine	Capsule Liquid	Approved (1st line option): Depression; bulimia nervosa; obsessive-compulsive disorder (OCD); off-label use in GAD	Prescribing guidelines for the management of depression NICE(CG90/91);(CG91);(CG185); (CG113)
	Paroxetine	Tablet Liquid	Approved: Depression; OCD; panic disorder; social anxiety disorder; PTSD, off-label use in GAD	Prescribing guidelines for the management of depression NICE(CG90);(CG91);(CG185); (CG113) (NG116)
	Sertraline	Tablet	Approved (1st line option): Depression; OCD; panic disorder; social anxiety disorder; PTSD, off-label use in GAD	Prescribing guidelines for the management of depression NICE(CG90);(CG91);(CG185); (CG113) (NG116)

BNF: 4.3.4 Other antidepressant medicines

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Presynaptic alpha 2-adrenoceptor blocker	Mirtazapine	Tablet	Approved: Severe depressive episode	Prescribing guidelines for the management of depression NICE(CG90);(CG91);(CG185)
Selective noradrenaline re-uptake inhibitor	Reboxetine	Tablet	Approved: Severe depressive episode	Prescribing guidelines for the management of depression NICE(CG90);(CG91);(CG185);(CG 113)
Serotonin & noradrenaline re-uptake inhibitor (SNRI)	Venlafaxine	Tablet Tablet MR (Capsules MR)	Approved: severe depressive episode; generalised anxiety disorder, social anxiety disorder	Prescribing guidelines for the management of depression Immediate release tablets should be prescribed 1st line. M/R tablets: Higher cost – only use where specifically required (MR capsules should <u>not</u> be prescribed) NICE(CG90);(CG91);(CG185); (CG113) (NG116)

	Duloxetine		Not approved	
noradrenaline & dopamine re-uptake inhibitor	Bupropion	MR tablet	Approved: severe depressive episode (off-label) Consultant initiation only – where NICE recommended treatments for mono or adjunctive therapy are ineffective or not tolerated.	Prescribing guidelines for the management of depression
Melatonin agonist, serotonin antagonist	Agomelatine		Not approved	(excluded from NICE guidance) NICE(TA231) – Terminated
Direct modulation of receptor activity & inhibition of serotonin transported	Vortioxetine	Tablet	Approved: (3rd line option) severe depressive episode (where inadequate response to 2 antidepressants within current episode)	Prescribing guidelines for the management of depression NICE TA367

BNF: 4.3.4 Antidepressants in the management of anxiety disorders

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Antidepressants	Citalopram* Fluoxetine* Paroxetine Sertraline* Venlafaxine (Escitalopram)	Tablets, capsules, oral liquids	Approved (1st / 2nd line option): (off-label*) use in generalised anxiety disorder (GAD) and panic disorder; (1st / 2nd line option) social anxiety disorder (NB. Escitalopram may only be prescribed for social anxiety disorder and only if other SSRIs not appropriate)	NICE(CG113) NICE(NG116)
MAOI	Phenelzine* Moclobemide		Approved (3rd line option): (off-label*) use in social anxiety disorder	NICE(NG116)

4.3.6 Medicines used in psychosis and related disorders

BNF: 4.3.6 Antipsychotic medicines

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Typical antipsychotics	Chlorpromazine	Tablet Oral solution	Approved: schizophrenia and related psychoses; mania; short term adjunctive management of psychomotor agitation, excitement and violent or dangerously impulsive	Trust guidance: Antipsychotic Prescribing guidelines; Rapid Tranquilisation guidelines

			behaviour;	Should never be given parenterally due to risk of severe hypotension and prolonged unconsciousness, plus reported association of high doses with sudden death. Also extremely painful parenterally. NICE(CG178)
	Flupentixol	Tablet <i>See section 4.3.6 for depot preparation</i>	Approved: schizophrenia and other psychoses; depression.	Trust guidance: Antipsychotic Prescribing guidelines NICE(CG178)
	Haloperidol	Tablet Capsule Oral liquid Injection <i>See section 4.3.6 for depot preparation</i>	Approved: schizophrenia and other psychoses; mania; short term adjunctive management of psychomotor agitation, excitement and violent or dangerously impulsive behaviour; short term adjunctive management of severe anxiety.	Trust guidance: Antipsychotic Prescribing guidelines; Rapid Tranquilisation guidelines NICE(CG178); (NG10)
	Sulpiride	Tablet Oral solution	Approved: schizophrenia	Trust guidance: Antipsychotic Prescribing guidelines NICE(CG178)
	Trifluoperazine hydrochloride	Tablet Oral solution	Approved: schizophrenia and other psychoses; short term adjunctive management of psychomotor agitation, excitement and violent or dangerously impulsive behaviour	Trust guidance: Antipsychotic Prescribing guidelines NICE(CG178)
	Zuclopenthixol dihydrochloride	Tablet	Approved: schizophrenia and other psychoses	Trust guidance: Antipsychotic Prescribing guidelines NICE(CG178)
	Zuclopenthixol acetate (Clopixol Acuphase ®)	Injection <i>See section 4.3.6 for depot preparation – zuclopenthixol deconoate</i>	Approved: short term management of acute psychoses, mania or exacerbations of chronic psychoses	Trust guidance: Antipsychotic Prescribing guidelines; Clopixol Acuphase guideline; Rapid Tranquilisation guidelines NICE(NG10)
Atypical antipsychotics	Amisulpride	Tablet Solution	Approved: schizophrenia; off-label use in psychoses Off-label use for short term treatment of persistent aggression in moderate to severe Alzheimer's dementia where risk of harm to self	Trust guidance: Antipsychotic Prescribing guidelines Short term use only in Alzheimer's Disease & to be reviewed regularly

			& others.	NICE(CG178)
Aripiprazole	Tablets Orodispersible tablets	Approved: schizophrenia; treatment & recurrence prevention of mania Off-label use for short term treatment of persistent aggression in moderate to severe Alzheimer's dementia where risk of harm to self & others. Adjunctive treatment in depression Challenging behaviour in adults with Learning Disabilities.		Trust guidance: Antipsychotic Prescribing guidelines. Short term use only in Alzheimer's Disease & to be reviewed regularly higher cost NICE(CG178); (CG90)
	Injection	Approved: control of agitation & disturbed behaviour in schizophrenia		Trust guidance: ; Rapid Tranquilisation guidelines Antipsychotic Prescribing guidelines
Clozapine	Tablet (Clozaril®)	Approved: schizophrenia (unresponsive to, or intolerant of conventional antipsychotics)		Trust guidance/policy: Antipsychotic Prescribing guidelines; Clozapine Treatment Guidelines. Clozaril® tablets: Patient, prescriber and supplying pharmacy must be registered with the Clozaril Patient Monitoring Service (CPMS) NICE(CG178)
	Liquid suspension (Denzapine ®)	Named patient only via a non-formulary request form: Denzapine® suspension only licensed preparation available.		Denzapine® suspension: Patient, prescriber and pharmacy must be registered with Denzapine Patient Monitoring Service (DMS).
Olanzapine	Tablet Orodispersible tablet	Approved: schizophrenia; treatment & recurrence prevention of mania; control of agitation & disturbed behaviour in schizophrenia or mania; off-label use in psychoses Off-label use for short term treatment of persistent aggression in moderate to severe Alzheimer's dementia where risk of harm to self & others. Adjunctive treatment in depression		Trust guidance: Antipsychotic Prescribing guidelines Short term use only in Alzheimer's Disease & to be reviewed regularly NICE(CG178); (NG10); (CG90)

		Injection (Zyprexa®)	Not Approved	
	Quetiapine	Tablet Modified release tablet	Approved: schizophrenia; treatment and prevention of mania and depression in bipolar disorder; Off-label use for short term treatment of persistent aggression in moderate to severe Alzheimer's dementia where risk of harm to self & others. Adjunctive treatment in depression (IR formulation approved for off-label use)	Trust guidance: Antipsychotic Prescribing guidelines Instant release tablets should be prescribed. M/R tablets: Higher cost - only use where specifically required (prescribe as 'MR tablets') NICE(CG178); (CG90)
	Risperidone	Tablet Orodispersible tablet Liquid <i>See section 4.3.6 for depot preparation</i>	Approved 1st line option: acute & chronic psychoses; mania; short term treatment of persistent aggression in moderate to severe Alzheimer's dementia where risk of harm to self & others; short term treatment of persistent aggression in conduct disorder. Adjunctive treatment in depression. Challenging behaviour in adults with Learning Disabilities.	Trust guidance: Antipsychotic Prescribing guidelines Short term use only in Alzheimer's Disease & to be reviewed regularly: Only licensed for short term (6 weeks) treatment of persistent aggression in Alzheimer's dementia / conduct disorder. NICE(CG178); (NG10); (CG90) (NG11)

BNF: 4.3.6 Antipsychotic depot injections

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Depot antipsychotics – typicals	Flupenthixol decanoate	Injection Injection (Depixol conc Injection (Depixol Low volume)	Approved (1st line option): maintenance in schizophrenia and other psychoses	Trust guidance: Depot antipsychotic medication guidelines; Antipsychotic Prescribing guidelines NICE(CG178)
	Haloperidol decanoate	Injection	Approved (1st line option): maintenance in schizophrenia and other psychoses	Trust guidance: Depot antipsychotic medication guidelines; Antipsychotic Prescribing guidelines NICE(CG178)
	Zuclopenthixol decanoate	Injection Injection (Clopixol conc®)	Approved (1st line option): maintenance in schizophrenia and other psychoses	Trust guidance: Depot antipsychotic medication

				guidelines; Antipsychotic Prescribing guidelines NICE(CG178)
Depot antipsychotics – atypicals	Aripiprazole long acting injection	Injection	Approved - maintenance treatment of schizophrenia and other psychoses in patients stabilised with oral aripiprazole.	Trust guidance: Depot antipsychotic medication guidelines; Antipsychotic Prescribing guidelines NICE(CG178)
	Risperidone long acting injection	Injection	Approved: maintenance in schizophrenia and other psychoses in patients tolerant to risperidone orally.	Trust guidance: Depot antipsychotic medication guidelines; Antipsychotic Prescribing guidelines NICE(CG178) Typical antipsychotic depots should be considered prior to initiating risperidone injection.
	Paliperidone long acting injection (monthly)	Injection	Approved- treatment of adults with schizophrenia and in patients that have a documented response and tolerability to risperidone.	Paliperidone oral tablets are NOT approved for use in C&I. Typical antipsychotic depots should be considered prior to initiating paliperidone palmitate due to the significant financial implications. Paliperidone is the active metabolite of risperidone. It has not demonstrated greater efficacy over other antipsychotics. NICE(CG178)
	Paliperidone prolonged release suspension for injection (three monthly)	Injection	Approved- Managed Use: for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly paliperidone palmitate injectable product. May only be initiated by a consultant after approval of a non-formulary form.	Reserved for patients unable to comply with monthly injections and susceptible to relapse.
	Olanzapine Embonate		Not Approved	

BNF: 4.3.6 Antipsychotics as antimanic medicines

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Antipsychotics	Haloperidol Olanzapine Quetiapine Risperidone Aripiprazole		Approved: treatment of mania; Olanzapine & aripiprazole are also licensed for prevention in patients whose manic episode responded to the respective medicine.	Aripiprazole higher cost NICE(CG178)

BNF: 4.3.6 Other antidepressant medicines

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Antipsychotic	Flupentixol	Tablet	Approved: depression; psychoses	NICE(CG90)(CG91) (CG178)

BNF: 4.4.2 Antimuscarinic medicines used in parkinsonism

Medicine Class	Medicines	Formulation	Approval status & indications	Additional information
Antimuscarinic medicines	Orphenadrine	Tablet Liquid	Approved: parkinsonism; drug induced extrapyramidal symptoms	Not tardive dyskinesia
	Procyclidine	Tablet Liquid Injection	Approved: parkinsonism; drug induced extrapyramidal symptoms	Not tardive dyskinesia
	Trihexyphenidyl (benzhexol hydrochloride)	Tablet Liquid	Approved: parkinsonism; drug induced extrapyramidal symptoms, clozapine induced hypersalivation (off-label)	Not tardive dyskinesia

BNF: 4.5 Medicines licensed in nausea & vertigo (prescribed off-label for the treatment of hypersalivation)

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Hyoscine	Hyoscine hydrobromide	Chewable tablet (Kwells®)	Approved: Off-label treatment of clozapine induced hypersalivation	

BNF: 4.7.1 Hypnotics

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Benzodiazepines	Temazepam CD	Tablet Oral solution	Approved (2nd line option): insomnia (short term use)	Trust guidance/policy: Guidelines for the Management of Insomnia; Controlled Drug policy

				NICE(TA77)
Z drugs	Zopiclone	Tablet	Approved (1st line option): insomnia (short term use)	Trust guidance/policy: Guidelines for the Management of Insomnia; NICE(TA77)
	Zolpidem tartrate	Tablet	Approved (3rd line option): insomnia (short term use)	Trust guidance/policy: Guidelines for the Management of Insomnia; NICE(TA77)
Antihistamine	Promethazine	Tablets, elixir	Approved – pregnant women (off-label indication)	NICE CG 192
Melatonin receptor agonist	Melatonin	MR tablets (licensed) Tablets, oral solution (unlicensed)	Approved – restricted use: Sleep disorders in patients with learning disabilities (off label indication)	NICE NG11 (NCL JFC approved)

BNF: 4.8.1 and 4.3.1 Medicines used in substance dependence

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Alcohol dependence	Acamprosate	Tablet	Approved: maintenance of abstinence in alcohol dependence	SMS only initiation NICE(CG115)
	Chlordiazepoxide	Capsule	Approved: alcohol detoxification	NICE(CG115) Guidelines for medically assisted community alcohol withdrawal. Inpatient alcohol withdrawal Prescribing Guidelines.
	Diazepam	Tablet Liquid	Approved: off-label use in alcohol detoxification;	NICE(CG115) Guidelines for medically assisted community alcohol withdrawal. Inpatient alcohol withdrawal Prescribing Guidelines.
	Lorazepam	Tablet	Approved: Off-label use in alcohol detoxification.	NICE(CG115) For use when liver function significantly impaired Inpatient alcohol withdrawal Prescribing Guidelines.
	Oxazepam	Tablet	Approved: off-label use in alcohol	For use when liver function

			detoxification;	significantly impaired Inpatient alcohol withdrawal Prescribing Guidelines.
	Disulfiram	Tablet	Approved: maintenance of abstinence in alcohol dependence	SMS only initiation NICE(CG115)
	Naltrexone	Tablet	Approved: Maintenance of abstinence in alcohol dependence	SMS only initiation NICE(CG115)
	Nalmefene	Tablets	Approved: Reduction of alcohol consumption	SMS initiation only NICE TA 325
Benzodiazepine dependence	Diazepam	Tablet Liquid	Approved: off-label use in benzodiazepine dependence	Prescribing Guidance for Substance Misuse Services

BNF: 4.8.2 Medicines used in nicotine dependence

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Nicotine dependence	Nicotine replacement therapy (NRT) Patches	Patches	Approved: treatment for smoking cessation	Restricted to inpatient and Community Smoking Cessation Team prescribing only for the treatment of smoking cessation. NICE (NG92)
	NRT Lozenges	Lozenge		
	NRT Gum	Gum		
	NRT Inhaler	Inhaler		
	NRT Nasal Spray	Nasal spray		
	NRT Oral spray	Oral spray		
	Varenicline	Tablets	Approved: treatment for smoking cessation	Trust guidance: Not recommended for acute inpatients NICE (NG92);(TA123)

BNF: 4.8.3 Medicines used in opioid dependence

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information	
Opioid Dependence	Buprenorphine (Subutex®) CD	Tablet sublingual	Approved: substitution treatment in opioid dependence	SMS only initiation NICE(CG52);(TA114)	
	Lofexidine	Tablet	Approved: management of symptoms in opioid detoxification	SMS only initiation NICE(CG52); No longer manufactured in UK	
	Diamorphine	Injection	Treatment of drug addiction by consultants with a special licence from the home office	SMS consultant approval and initiation	
	Methadone CD	Oral solution sugar free, Oral solution Concentrated oral solution		Approved: substitution treatment in opioid dependence	SMS only initiation or following Trust protocol: Opiate Addiction - Management of hospital inpatients Concentrated oral solution (SMS) restricted use only NICE(CG52);(TA114)
		Tablets		Approved – Restricted use: off label use in substitution treatment in opioid dependence	SMS only Restricted use only (travel where liquid volume an issue) NICE(TA114)
		Ampoules		Approved- Restricted use (SMS Consultant approval): off label* / substitution treatment in opioid dependence	SMS Consultant only approval and initiation * Preparations not licensed for use in opioid dependence
	Morphine Sulphate Modified Release CD	Morphine sulphate MR tablets		Approved – Restricted use: Off-label use for detoxification in opioid dependence following chronic pain management.	SMS only initiation Restricted use only (jointly managed chronic pain clients)
Naltrexone	Tablet		Approved: relapse prevention in opioid dependence	SMS only initiation NICE (TA114) , (TA115)	

BNF: 7.4.1 Phosphodiesterase Type-5 Inhibitors

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Phosphodiesterase Type-5 Inhibitors	Sildenafil (1 st line)	tablets	Indicated for as required management of erectile dysfunction.	

Phosphodiesterase Type-5 Inhibitors	Tadalafil (2 nd line)	tablets	Indicated for as required management of erectile dysfunction if patients experience an idiosyncratic reaction to prn sildenafil.	
--	----------------------------------	---------	--	--

BNF: 9.6.2 Vitamin B group

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Vitamin B group	Thiamine	Tablets	Approved: Treatment & prophylaxis of Wernicke/Korsakoff	NICE(CG100)
	Vitamin B compound strong	Tablets	Approved: prophylactic supplement during detoxification	
	Pabrinex®	I/M high potency injection	Approved: Treatment & prophylaxis of Wernicke/Korsakoff	Caution: anaphylaxis may occur following injection, facilities to treat must be available when administered. NICE(CG100)

BNF: 10.3.4

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Gamma-hydroxy butyrate (GHB) dependence	Baclofen	Tablets	Approved: off-label use in treatment of GHB withdrawal symptoms	Management and detoxification of GHB and GBL guidelines

Diazepam – see BNF 4.3.1.

Medicines used in opioid dependence

Medicine Class	Medicine	Formulation	Approval status & indications	Additional information
Hypnotics BNF section 4.7.1	Zopiclone	Tablet	Approved: insomnia during opioid withdrawal	
Antispasmodics BNF section 1.6	Mebeverine	Tablet	Approved: off label use for abdominal cramps due to opioid withdrawal	
	Hyoscine butylbromide	Tablet (Buscopan®)	Approved: abdominal cramps due to opioid withdrawal	
Antimotility medicines BNF section 1.3	Co-phenotrope	Tablet (diphenoxylate , atropine)	Approved: diarrhoea due to opioid withdrawal	
	Loperamide	Tablet	Approved: diarrhoea due to opioid withdrawal	

Medicines used in nausea & vertigo BNF section 4.5	Metoclopramide	Tablet	Approved: nausea & vomiting due to opioid withdrawal	
Analgesics BNF section 4.6	Paracetamol	Tablets Dispersible tablets	Approved: aches and pains due to opioid withdrawal	Dispersible tablets higher cost
NSAID BNF section 10.4	Ibuprofen	Tablets	Approved: aches and pains due to opioid withdrawal	MR tablet should not be prescribed – higher cost